Non-Small Cell Lung Cancer – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Non-Small Cell Lung Cancer – Pipeline Review, H1 2020’, provides an overview of the Non-Small Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer

– The report reviews pipeline therapeutics for Non-Small Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Non-Small Cell Lung Cancer therapeutics and enlists all their major and minor projects

– The report assesses Non-Small Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4D Pharma Plc

4SC AG

A&G Pharmaceutical Inc

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Ability Pharmaceuticals SL

ABM Therapeutics Inc

AC Bioscience SA

ACEA Therapeutics Inc

Achilles Therapeutics Ltd

AcuityBio Corp

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Aduro BioTech Inc

Advanced BioDesign

Advaxis Inc

Advenchen Laboratories LLC

Adze Biotechnology Inc

Agenus Inc

Agilvax Inc

Agios Pharmaceuticals Inc

AIM ImmunoTech Inc

Akeso Inc

Alethia Biotherapeutics Inc

Alkermes Plc

Alligator Bioscience AB

Allist Shanghai Pharmaceutical Technology Co Ltd

Almac Discovery Ltd

Alpha Biopharma

Alphamab Oncology

Altum Pharmaceuticals Inc

ALX Oncology Inc

amcure GmbH

Amgen Inc

AmMax Bio Inc

Amphivena Therapeutics Inc

Andarix Pharmaceuticals Inc

Anew Oncology Inc

AnHeart Therapeutics Inc

Anhui Anke Biotechnology (Group) Co Ltd

Antapodia Therapeutics Inc

Antengene Corp

AP Biosciences Inc

Apexigen Inc

Apollomics Inc

Apotex Inc

Aprea Therapeutics AB

Aptarion biotech AG

Araxes Pharma LLC

Arch Oncology Inc

Arcus Biosciences Inc

Aro Biotherapeutics Co

Arvinas Inc

Asana BioSciences LLC

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Astellas Pharma Inc

AstraZeneca Plc

Atreca Inc

AUM Biosciences Pte Ltd

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

Axelar AB

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Biostar Technologies Ltd

Beijing Eastern Biotech Co Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Beijing Luzhu Biotechnology Co Ltd

Beijing Mabworks Biotech Co Ltd

Beijing Pearl Biotechnology LLC

BerGenBio ASA

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

BeyondSpring Inc

Bicycle Therapeutics Plc

Binjiang Pharma, Inc.

Bio-Path Holdings Inc

Bio-Thera Solutions Ltd

BioAtla LLC

Biocad

BIOCND Inc

Biocon Ltd

Biohaven Pharmaceutical Holding Company Ltd

BioIntegrator Ltd

BioInvent International AB

BioLineRx Ltd

BioMarck Pharmaceuticals Ltd

BioMed Valley Discoveries Inc

BioNTech SE

Biosion Inc

Biothera Pharmaceutical Inc

Bioven Group

BioXpress Therapeutics SA

BJ Bioscience Inc

Blueprint Medicines Corp

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Boston Pharmaceuticals Inc

BriaCell Therapeutics Corp

Bridge Biotherapeutics Inc

BrightPath Biotherapeutics Co Ltd

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

Candel Therapeutics

Cantargia AB

CARsgen Therapeutics Ltd

CAS-Lamvac Biotech Co Ltd

Cascade Prodrug Inc

CDR-Life Inc

Cellatoz Therapeutics Inc

Celldex Therapeutics Inc

Cellestia Biotech AG

Cellmid Ltd

Celltrion Inc

Cellular Biomedicine Group Inc

Cellworks Group Inc

Celon Pharma SA

Centaurus Biopharma Co Ltd

Centurion BioPharma Corp

Centus Biotherapeutics Ltd

Checkmate Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Chi Cheung (Shanghai) Biomedical Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Chineo Med Beijing Co Ltd

Chiome Bioscience Inc

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

Cipla BioTec Pvt Ltd

Cleveland BioLabs Inc

Cloaked Therapeutics LLC

Clovis Oncology Inc

Co-D Therapeutics Inc

Compugen Ltd

Constellation Pharmaceuticals Inc

Convert Pharmaceuticals SA

Corcept Therapeutics Inc

Cortice Biosciences Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

CSPC Pharmaceutical Group Ltd

CStone Pharmaceuticals Co Ltd

Cumberland Pharmaceuticals Inc

Cureport Inc

Cyclica Inc

Cytocom Inc

Cytocraft Bio-Tech Development Co Ltd

CytomX Therapeutics Inc

DAE HWA Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Debiopharm International SA

Deciphera Pharmaceuticals Inc

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Delta-Fly Pharma Inc

DiNonA Inc

Dizal (Jiangsu) Pharmaceutical Co Ltd

Domainex Ltd

Dr. Reddy's Laboratories Ltd

Dragonfly Therapeutics Inc

Druggability Technologies Holdings Ltd

Dynavax Technologies Corp

eFFECTOR Therapeutics Inc

EirGenix Inc

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Eli Lilly and Co

Elicio Therapeutics

EnGeneIC Ltd

Enochian Biosciences Inc

EntreChem SL

Enzene Biosciences Ltd

EpicentRx Inc

Epidestiny Inc

EpimAb Biotherapeutics Inc

Epizyme Inc

Epygen Biotech Pvt Ltd

Ergon Pharmaceuticals LLC

Esanex Inc

Essential Biotechnology LLC

Eudendron Srl

Eutilex Co Ltd

Evaxion Biotech ApS

Evelo Biosciences Inc

Evestra Inc

Evotec SE

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FibroStatin SL

Five Prime Therapeutics Inc

Fochon Pharma Inc

Fochon Pharmaceutical Ltd

Forbius

Formosa Pharmaceuticals Inc

Fresenius SE & Co KGaA

Fujifilm Holdings Corp

G&E Corp

G1 Therapeutics Inc

Galectin Therapeutics Inc

Galera Therapeutics Inc

GC Pharma

GEEN Biotechnology Inc

GEMoaB Monoclonals GmbH

Gene Techno Science Co Ltd

GeneFrontier Corp

Genelux Corp

Genentech Inc

Geneos Therapeutics Inc

Genexine Inc

GenFleet Therapeutics (Shanghai) Inc

Genmab AS

Genocea Biosciences Inc

Genome & Co

Genor BioPharma Co Ltd

Genosco Inc

Genprex Inc

Table of Contents

Table of Contents

Introduction

Non-Small Cell Lung Cancer - Overview

Non-Small Cell Lung Cancer - Therapeutics Development

Non-Small Cell Lung Cancer - Therapeutics Assessment

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development

Non-Small Cell Lung Cancer - Drug Profiles

Non-Small Cell Lung Cancer - Dormant Projects

Non-Small Cell Lung Cancer - Discontinued Products

Non-Small Cell Lung Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020

Non-Small Cell Lung Cancer – Pipeline by 3SBio Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by 4D Pharma Plc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by 4SC AG, H1 2020

Non-Small Cell Lung Cancer – Pipeline by A&G Pharmaceutical Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Non-Small Cell Lung Cancer – Pipeline by AbbVie Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Ability Pharmaceuticals SL, H1 2020

Non-Small Cell Lung Cancer – Pipeline by ABM Therapeutics Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by AC Bioscience SA, H1 2020

Non-Small Cell Lung Cancer – Pipeline by ACEA Therapeutics Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Achilles Therapeutics Ltd, H1 2020

Non-Small Cell Lung Cancer – Pipeline by AcuityBio Corp, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by ADC Therapeutics SA, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Aduro BioTech Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Advanced BioDesign, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Advaxis Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Advenchen Laboratories LLC, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Adze Biotechnology Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Agenus Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Agilvax Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Agios Pharmaceuticals Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by AIM ImmunoTech Inc, H1 2020

Non-Small Cell Lung Cancer – Pipeline by Akeso Inc, H1 2020

List of Figures

List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports